Cadonilimab plus chemotherapy ± bevacizumab as 1L treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): a randomized, double-blind, placebo-controlled phase 3 study (Compassion-16)

被引：0
|
作者：
Wu, Xiaohua [1 ]
Sun, Yang [2 ]
Yang, Hongying [3 ]
Wang, Jing [4 ,5 ]
Lou, Hanmei [6 ]
Li, Dan [7 ]
Wang, Ke [8 ]
Zhang, Hui [9 ]
Wu, Tao [10 ]
Li, Yuzhi [11 ]
Wang, Chunyan [12 ]
Li, Guiling [13 ]
Wang, Yifeng [14 ]
Li, Dapeng [15 ]
Tang, Ying [16 ]
Pan, Mei [17 ]
Cai, Hongyi [18 ]
Liu, Ting [19 ]
Xia, Michelle [19 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fujian Med Univ, Clin Oncol Sch, Fujian Canc Hosp, Fuzhou, Peoples R China
[3] Yunnan Canc Hosp, Kunming, Peoples R China
[4] Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[5] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[6] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[7] Southwest Med Univ, Affiliated Hosp, Luzhou, Peoples R China
[8] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[10] Changde First Peoples Hosp, Changde, Peoples R China
[11] Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China
[12] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[13] Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[14] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China
[15] Shandong First Med Univ, Canc Hosp, Jinan, Peoples R China
[16] Chongqing Univ, Affiliated Canc Hosp, Chongqing, Peoples R China
[17] Jiangxi Maternal & Child Hlth Hosp, Nanchang, Peoples R China
[18] Gansu Prov Hosp, Lanzhou, Peoples R China
[19] Akeso Biopharm Inc, Zhongshan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB014/#167
引用
收藏
页码：A1 / A2
页数：2
相关论文
共 50 条
  • [41] A phase 2, double-blind, randomized, placebo-controlled, dose-finding study of sotatercept for the treatment of patients with chemotherapy-induced anemia and metastatic breast cancer.
    Auerbach, M.
    Osborne, C. R. C.
    Klesczewski, K.
    Laadem, A.
    Sherman, M. L.
    Bianca, R.
    CANCER RESEARCH, 2012, 72
  • [42] Targeting of Rifamycin SV to the Colon for Treatment of Travelers' Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
    DuPont, Herbert L.
    Petersen, AnnKatrin
    Zhao, Jeff
    Mundt, Arley
    Jiang, Zhi-Dong
    Miller, Stephan
    Flores, Jose
    Shringarpure, Reshma
    Moro, Luigi
    Bagin, Robert G.
    Ballard, E. David
    Totoritis, Mark C.
    JOURNAL OF TRAVEL MEDICINE, 2014, 21 (06) : 369 - 376
  • [43] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (PANORAMA 1)
    San-Miguel, J.
    Hungria, V. T.
    Yoon, S. S.
    Beksac, M.
    Dimopoulos, M. A.
    Elghandour, A.
    Jedrzejczak, W. W.
    Guenther, A.
    Nakorn, T. Na
    Siritanaratkul, N.
    Schlossman, R. L.
    Hou, J.
    Moreau, P.
    Lonial, S.
    Lee, J. H.
    Einsele, H.
    Salwender, H.
    Sopala, M.
    Bengoudifa, B. R.
    Corrado, C.
    Binlich, F.
    Richardson, P.
    HAEMATOLOGICA, 2014, 99 : 219 - 220
  • [44] Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
    Sachs, Gary S.
    Yeung, Paul P.
    Rekeda, Ludmyla
    Khan, Arifulla
    Adams, Julie L.
    Fava, Maurizio
    AMERICAN JOURNAL OF PSYCHIATRY, 2023, 180 (03): : 241 - 251
  • [45] Responder Analysis of Estradiol Spray for the Treatment of Vasomotor Symptoms: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Taylor, Hugh S.
    Spigelman, Samuel
    McMillin, Tara
    Faragasso, Anthony M.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2016, 23 (12): : 1401 - 1401
  • [46] Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-blind, Multicenter, Placebo-Controlled Phase 3 Study
    Mueller, Daniel S.
    Prinz, Valentina
    Adelglass, Jeffrey
    Cox, Sue Ellen
    Gold, Michael H.
    Kaufman-Janette, Joely
    Nestor, Mark S.
    Taylor, Susan
    Frank, Konstantin
    AESTHETIC SURGERY JOURNAL, 2022, 42 (06) : 677 - 688
  • [47] Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).
    Even, Caroline
    Harrington, Kevin Joseph
    Massarelli, Erminia
    Hesselink, Marielle Klein
    Visscher, Sonja
    Fury, Matthew G.
    Sanders, Femke
    Laban, Simon
    Fayette, Jerome
    Oliva, Marc
    Licitra, Lisa F.
    Melichar, Bohuslav
    Kong, Anthony
    Devriese, Lot A.
    Brana, Irene
    Jankowska, Petra
    Posner, Marshall R.
    Hooftman, Leon W.
    Melief, Cornelis J. M.
    Ferrarotto, Renata
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia
    Taylor, K
    Ganly, P
    Charu, V
    DiBenedetto, J
    Kracht, K
    Rossi, G
    Hernandez, E
    BLOOD, 2005, 106 (11) : 992A - 993A
  • [49] A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy
    Martin, A. Gonzalez
    Rojas, L. A.
    Braly, P. S.
    Barter, J.
    O'Malley, D. M.
    Oza, A. M.
    Haggerty, A. F.
    Vulsteke, C.
    Provencher, D. M.
    Graybill, W.
    Li, Y.
    Malinowska, I. A.
    Mirza, M. R.
    Vergote, I.
    Pothuri, B.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer
    Xu, Rui-Hua
    Shen, Lin
    Wang, Keming
    Wu, Gang
    Shi, Chunmei
    Ding, Kefeng
    Lin, Lizhu
    Wang, Jinwan
    Xiong, Jianping
    Wu, Changping
    Li, Jin
    Liu, Yunpeng
    Wang, Dong
    Ba, Yi
    Feng, Jueping
    Bai, Yuxian
    Bi, JingWang
    Ma, Liwen
    Lei, Jian
    Yu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345